In addition to our tools and blog, ML&P occasionally delves into complex topics, posting brief explanations to make their legal implications more clear and understandable. We also undertake longer research projects, to more thoroughly explore issues and make policy recommendations. These are posted below.
The ‘Oxford / AstraZeneca’ vaccine is one of the world’s leading hopes in the race to end the Covid-19 pandemic. Its history is not as clear, though, as it may first seem. Medicines Law & Policy has written a technical briefing note that contextualises the respective roles of Oxford University, the Jenner Institute, AstraZeneca and these other actors, and provides comments as well as raises some important questions about what might yet be done better and what lessons can be learned for the future. Click here to read it.
In June 2019, Medicines Law & Policy published a series of briefing documents that aim to contribute to the discussion on high medicines prices, in particular those that result from market exclusivity. The publication makes recommendations for policy and legislative change in the areas of Supplementary Protection Certificate, Data Exclusivity, and Orphan Medicinal Product regulations. The documents can be downloaded in their entirety, or by section, using the links below. A presentation on the documents made at a 3 June event co-hosted by the European Public Health Alliance is available here.
